Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 15Breast Neoplasms 7Sarcoma 5Neoplasm Metastasis 4Carcinoma, Ovarian Epithelial 4Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Multi-centric Castleman's Disease 2Hodgkin Disease 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Uterine Cervical Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Osteosarcoma 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphadenopathy 1

Interventions

pembrolizumab 45Specimen Handling 45Biopsy 37Magnetic Resonance Spectroscopy 36Paclitaxel 22Nivolumab 21Carboplatin 21Gemcitabine 20Radiosurgery 18Irinotecan 16Ipilimumab 13Cisplatin 13Capecitabine 12130-nm albumin-bound paclitaxel 12trastuzumab deruxtecan 11Taxes 11Pemetrexed 11Cetuximab 11olaparib 10Leucovorin 10Fluorouracil 10Cyclophosphamide 10durvalumab 9Oxaliplatin 9Bevacizumab 9abemaciclib 8X-Rays 8Fulvestrant 8Drug Therapy 8palbociclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × liposomal doxorubicin × 90 days × Clear all
NCT07213804 2026-05-27

FRAmework-01

Eli Lilly and Company

Phase 3 Recruiting
1,080 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04895358 2026-03-11

KEYNOTE-B49

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
340 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡